Take-Two Interactive Software, Inc. to Report First Quarter
About Take-Two Interactive Software
Headquartered in New York City, Take-Two Interactive Software, Inc. is a leading developer, publisher, and marketer of interactive entertainment for consumers around the globe. The Company develops, operates, and publishes products principally through Rockstar Games, 2K, and Zynga. Our products are currently designed for console gaming systems, PC, and mobile, including smartphones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The Company's common stock is publicly traded on NASDAQ under the symbol TTWO.
All trademarks and copyrights contained herein are the property of their respective holders.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice ® platforms—including RenMab™ (fully human antibody), RenLite ® (common light chain), RenNano ® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice ® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice ® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
New York Post
an hour ago
- New York Post
Stocks surge, euro steady after US-EU trade agreement
Global stocks rose and the euro appreciated on Monday after a trade agreement between the United States and the EU lifted sentiment and provided some clarity in a week of key policy meetings by the Federal Reserve and the Bank of Japan. The US struck a framework trade agreement with the European Union, imposing a 15% import tariff on most EU goods – half the threatened rate, a week after agreeing to a similar trade deal with Japan. Countries are scrambling to finalise trade deals ahead of an August 1 deadline set by US President Donald Trump, with talks between the US and China set for Monday in Stockholm amid expectations of another 90-day extension to the truce between the world's top two economies. 3 President Donald Trump (R) shakes hands with European Commission President Ursula von der Leyen (L) following their meeting, in Turnberry, south west Scotland on July 27, 2025. AFP via Getty Images 'A 15% tariff on European goods, forced purchases of US energy and military equipment and zero tariff retaliation by Europe, that's not negotiation, that's the art of the deal,' said Prashant Newnaha, senior Asia-Pacific rates strategist at TD Securities. 'A big win for the US.' European futures surged more than 1%, while S&P 500 futures rose 0.5% and Nasdaq futures advanced 0.6%. The euro strengthened across the board, rising against the dollar, sterling and yen. 'We have to be a bit cautious from here,' said Sim Moh Siong, currency strategist at Bank of Singapore, of the broader risk-on rally. 'A lot of good news is already in the price.' MSCI's broadest index of Asia-Pacific shares outside Japan was up 0.32%, just shy of the almost four-year high it touched last week. Japan's Nikkei fell 1% after hitting a one-year high last week. While the baseline 15% tariff will still be seen by many in Europe as too high, compared with Europe's initial hopes to secure a zero-for-zero tariff deal, it is better than the threatened 30% rate. 3 Currency traders work near a screen showing the Korea Composite Stock Price Index (KOSPI) and the foreign exchange rate between US dollar and South Korean won, right, at the foreign exchange dealing room of the Hana Bank headquarters in Seoul, South Korea, Monday, July 28, 2025. AP The US-EU deal provides clarity to companies and averts a bigger trade war between the two allies that account for almost a third of global trade. 'A major tail-risk has now been defused,' said Marc Velan, head of investments at Lucerne Asset Management in Singapore. 'Markets are interpreting this as a sign of stability and predictability returning to trade policy,' he added. 'The China delay fits the same pattern: the administration is opting for controlled diplomacy over confrontation.' 3 The US struck a framework trade agreement with the European Union, imposing a 15% import tariff on most EU goods – half the threatened rate, a week after agreeing to a similar trade deal with Japan. AP Gains for China's blue-chip stocks petered out towards the midday break, while Hong Kong's Hang Seng index gained 0.5%. The Australian dollar , often seen as a proxy for risk appetite, was at $0.657, hovering around the near eight-month peak scaled last week. FED, BOJ AWAIT In an action-packed week, investors will watch out for the monetary policy meetings from the Fed and the BOJ as well as the monthly US employment report and earnings from megacap companies Apple, Microsoft and Amazon. While the Fed and the BOJ are expected to maintain rates, comments from the officials will be crucial for investors to gauge the interest rate path. The trade deal with Japan has opened the door for the BOJ to raise rates again this year. Meanwhile, the Fed is likely to be cautious on any rate cuts as officials seek more data to determine tariffs' impact on inflation before they ease rates further. But tensions between the White House and the central bank over monetary policy have increased, with Trump repeatedly lashing out at Fed Chair Jerome Powell for not cutting rates. Two of the Fed Board's Trump appointees have articulated reasons for supporting a rate cut this month. In commodities, oil prices rose after the US-EU trade agreement. Brent crude futures and US West Texas Intermediate crude both rose 0.5%. Gold prices fell on Monday to their lowest in nearly two weeks on reduced appetite for safe havens.
Yahoo
an hour ago
- Yahoo
OMS Energy Technologies Inc. Announces Fiscal Year 2025 Financial Results
SINGAPORE, July 28, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. ('OMS' or the 'Company') (NASDAQ: OMSE), a growth-oriented manufacturer of surface wellhead systems ('SWS') and oil country tubular goods ('OCTG') for the oil and gas industry, today announced its financial results for the fiscal year ended March 31, 2025. Fiscal Year 2025 Financial Highlights Total revenues in 2025 were $203.6 million, compared with $18.2 million for the period from April 1, 2023, through June 15, 2023, and $163.3 million for the period from June 16, 2023, through March 31, 2024. Gross margin in 2025 was 33.9%, compared with 27.6% for the period from April 1, 2023, through June 15, 2023, and 29.9% for the period from June 16, 2023, through March 31, 2024. Operating profit in 2025 was $59.9 million, compared with $3.2 million for the period from April 1, 2023, through June 15, 2023, and $40.2 million for the period from June 16, 2023, through March 31, 2024. Mr. How Meng Hock, Chairman and Chief Executive Officer of OMS, commented, 'We are extremely proud to report strong results for fiscal year 2025 in our first earnings announcement as a publicly listed company. Our double-digit revenue growth, expanded gross margin, and increase in operating profit are a direct result of our team's disciplined execution and commitment to delivering value across all areas of our business. We have also recorded several new customer wins and contract renewals since our IPO in May, further broadening and diversifying our revenue base. With our focus on long-term growth, we're entering fiscal 2026 with strong momentum and a clear strategy for continued innovation and expansion.' Mr. Kevin Yeo, Chief Financial Officer, added, 'Our fiscal 2025 financial performance reflects both top-line strength and meaningful margin improvement. Total revenues grew to $203.6 million, with gross margin reaching 33.9%. Operating profit increased to $59.9 million, highlighting our enhanced cost discipline and the benefits of growing economies of scale. Our net profit for the year was $47.0 million. When excluding a one-time $49.4 million bargain purchase gain recognized in fiscal 2024 related to the Management Buyout, our underlying profitability in 2025 demonstrates strong growth momentum. Supported by these solid fundamentals, a healthy balance sheet and loyal customer base, we remain confident of driving sustainable growth and building long-term shareholder value.' Fiscal Year 2025 Financial Results Total revenues. Total revenues in 2025 were $203.6 million, compared with $18.2 million for the period from April 1, 2023, through June 15, 2023, and $163.3 million for the period from June 16, 2023, through March 31, 2024. Specialty connectors and pipes. Revenues from sales of specialty connectors and pipes in 2025 were $143.1 million, compared with $5.1 million for the period from April 1, 2023, through June 15, 2023, and $113.5 million for the period from June 16, 2023, through March 31, 2024. This increase was primarily due to a significant increase in demand from one of the Company's major customers who had higher levels of business activities related to oil and gas production. Surface wellhead and Christmas tree equipment. Revenues from sales of surface wellhead and Christmas tree equipment in 2025 were $8.7 million, compared with $3.0 million for the period from April 1, 2023, through June 15, 2023, and $6.8 million for the period from June 16, 2023, through March 31, 2024. This decrease was primarily due to delayed demand from one of the Company's major customers in Indonesia, who is rationalizing their requirements as they plan for increased production to meet Indonesia's energy security plan, as well as a delayed shipment to the Middle East which will materialize in the fiscal year 2026. Premium threading services. Revenues from rendering of premium threading services in 2025 were $36.8 million, compared with $7.6 million for the period from April 1, 2023, through June 15, 2023, and $31.1 million for the period from June 16, 2023, through March 31, 2024. This slight decrease was primarily attributable to a relatively stable level of rig activities across oil and gas customers in the countries that drive demand for the Company's premium threading services. Other ancillary services. Revenues generated from other ancillary services in 2025 were $15.0 million, compared with $2.4 million for the period from April 1, 2023, through June 15, 2023, and $11.9 million for the period from June 16, 2023, through March 31, 2024. This increase was primarily due to greater customer demand for engineering testing, inspection and maintenance services. Cost of revenues. Cost of revenues in 2025 was $134.6 million, compared with $13.2 million for the period from April 1, 2023, through June 15, 2023, and $114.5 million for the period from June 16, 2023, through March 31, 2024. Gross profit. Gross profit in 2025 was $69.0 million, compared with $5.0 million for the period from April 1, 2023, through June 15, 2023, and $48.7 million for the period from June 16, 2023, through March 31, 2024. Gross margin in 2025 was 33.9%, compared with 27.6% for the period from April 1, 2023, through June 15, 2023, and 29.9% for the period from June 16, 2023, through March 31, 2024. The increase was mainly due to the growth in total revenues, as well as the benefits from economies of scale stemming from higher sales volume, sourcing productivity and an increase in the proportion of higher-margin services performed. Selling, general and administrative expenses. Selling, general and administrative expenses in 2025 were $9.1 million, compared with $1.8 million for the period from April 1, 2023, through June 15, 2023, and $8.6 million for the period from June 16, 2023, through March 31, 2024. The decrease was mainly due to a decrease in legal and professional fees, staff expenses and depreciation. Operating profit. Operating profit in 2025 was $59.9 million, compared with $3.2 million for the period from April 1, 2023, through June 15, 2023, and $40.2 million for the period from June 16, 2023, through March 31, 2024. Total other income/(expense), net. Total other income, net in 2025 was $0.2 million, compared with total other expense, net of $0.08 million for the period from April 1, 2023, through June 15, 2023, and total other income, net of $50.2 million for the period from June 16, 2023, through March 31, 2024. The change was primarily due to a non-recurring bargain purchase gain of $49.4 million related to the management buyout in the period from June 16, 2023, through March 31, 2024. Net profit. Net profit in 2025 was $47.0 million, compared with $2.4 million for the period from April 1, 2023, through June 15, 2023, and $82.1 million for the period from June 16, 2023, through March 31, 2024. Basic and diluted EPS. Basic and diluted earnings per share were both $1.18 in 2025, compared with $2.19 for the period June 16, 2023, through March 31, 2024. Balance Sheet and Cash Flow As of March 31, 2025, the Company's cash and cash equivalents and restricted cash totaled $75.8 million, compared with $45.4 million as of March 31, 2024. Net cash provided by operating activities was $40.5 million, compared with net cash used of $2.9 million for the period from April 1, 2023, through June 15, 2023, and net cash provided of $24.0 million for the period from June 16, 2023, through March 31, 2024. About OMS Energy Technologies Inc. OMS Energy Technologies Inc. (NASDAQ: OMSE) is a growth-oriented manufacturer of surface wellhead systems (SWS) and oil country tubular goods (OCTG) for the oil and gas industry. Serving both onshore and offshore exploration and production operators, OMS is a trusted single-source supplier across six vital jurisdictions in the Asia Pacific, Middle Eastern and North African (MENA) regions. The Company's 11 strategically located manufacturing facilities in key markets ensure rapid response times, customized technical solutions and seamless adaptation to evolving production and logistics needs. Beyond its core SWS and OCTG offerings, OMS also provides premium threading services to maximize operational efficiency for its customers. For more information, please visit Safe Harbor Statement This press release contains statements that may constitute 'forward-looking' statements which are made pursuant to the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'likely to,' and similar statements. Statements that are not historical facts, including statements about the Company's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: OMS Energy Technologies RelationsEmail: ir@ Piacente Financial CommunicationsBrandi PiacenteTel: +1-212-481-2050Email: oms@ Hui FanTel: +86-10-6508-0677Email: oms@ Unaudited Summary of Financial ResultsConsolidated Statements of Financial Positions For theyear endedMarch 31, 2025 For theyear endedMarch 31, 2024 US$'000 US$'000 Assets Current assets: Cash and cash equivalents 72,950 43,470 Restricted cash, current 1,692 1,593 Trade receivables 13,467 31,948 Contract assets 983 1,730 Inventories 32,546 30,689 Prepayment and other current assets 1,646 3,067 Amount due from a related party 1,584 1,585 Total Current Assets 124,868 114,082 Non-current assets: Restricted cash, non-current 1,189 367 Right-of-use assets 8,086 3,549 Property, plant and equipment 32,055 32,040 Intangible assets 42 126 Deferred tax assets 2,938 2,574 Prepayment and other non-current assets 1,327 694 Total Non-Current Assets 45,637 39,350 Total Assets 170,505 153,432 Liabilities Current Liabilities: Trade and other payables 15,070 47,535 Loans and borrowings — 6,504 Tax payable 8,200 6,669 Lease liabilities, current 1,187 741 Total Current Liabilities 24,457 61,449 Non-current Liabilities: Employee benefits obligation 827 751 Lease liabilities, non-current 6,096 1,843 Deferred tax liabilities 4,217 3,684 Other payables, non-current — 5,000 Provisions 321 351 Total Non-Current Liabilities 11,461 11,629 Total Liabilities 35,918 73,078 Equity Share capital 4 4 Share premium 72,648 67,648 Retained earnings 58,634 13,818 Accumulated other comprehensive loss (2,397 ) (4,441 ) Equity attributable to Shareholders of the Company 128,889 77,029 Non-controlling interests 5,698 3,325 Total equity 134,587 80,354 Total liabilities and equity 170,505 153,432 Consolidated Statements of Profit or Loss and Other Comprehensive Income Successor Successor Predecessor For theyear endedMarch 31, 2025 For the periodJune 16, 2023throughMarch 31, 2024 For the periodApril 1throughJune 15, 2023 US$'000 US$'000 US$'000 Revenue – third parties 203,607 163,267 16,967 Revenue – related parties — — 1,215 Total revenue 203,607 163,267 18,182 Cost of revenue – third parties (134,620 ) (114,525 ) (13,080 ) Cost of revenue – related parties — — (75 ) Total cost of revenue (134,620 ) (114,525 ) (13,155 ) Gross profit 68,987 48,742 5,027 Selling, general and administrative expenses (9,122 ) (8,574 ) (1,790 ) Operating profit 59,865 40,168 3,237 Bargain purchase gain — 49,429 — Other income/(expenses), net – third parties 246 775 (108 ) Other income, net – related parties — — 29 Total other income/(expenses), net 246 50,204 (79 ) Finance income – third parties 339 55 9 Finance income – related parties — — 65 Total finance income 339 55 74 Finance cost – third parties (284 ) (915 ) (38 ) Finance cost – related parties — — (162 ) Total finance cost (284 ) (915 ) (200 ) Profit before tax 60,166 89,512 3,032 Income tax expense (13,189 ) (7,424 ) (657 ) Net profit 46,977 82,088 2,375 Other comprehensive income/(loss): Items that will not be reclassified to profit or loss Foreign currency translation differences 2,258 (1,701 ) (610 ) Changes resulting from actuarial remeasurement of employee benefits obligation (2 ) (33 ) (9 ) Other comprehensive income/(loss), net of tax 2,256 (1,734 ) (619 ) Total comprehensive income 49,233 80,354 1,756 Net profit attributable to: Shareholders of the Company 44,816 80,880 1,867 Non-controlling interests 2,161 1,208 508 Net profit 46,977 82,088 2,375 Total comprehensive income attributable to: Shareholders of the Company 46,860 79,184 1,310 Non-controlling interests 2,373 1,170 446 Total comprehensive income 49,233 80,354 1,756 Basic and diluted weighted-average shares outstanding 37,822,500 36,900,000 Basic and diluted earnings per share (as adjusted) (US$) 1.18 2.19 Consolidated Statements of Cash Flows Successor Successor Predecessor For theyear endedMarch 31, 2025 For the periodJune 16, 2023throughMarch 31,2024 For the periodApril 1throughJune 15,2023 US$'000 US$'000 US$'000 Operating activities Net profit 46,977 82,088 2,375 Adjustments for: Income tax expenses 13,189 7,424 657 Depreciation of property, plant and equipment 2,711 3,800 251 Amortization of intangible assets 84 97 6 Depreciation of right-of-use assets 1,412 1,030 140 Loss/(gain) on disposal of property, plant and equipment 111 (357 ) — Allowance for/(reversal of) inventories obsolescence 571 (335 ) (6 ) Allowance for/(reversal of) expected credit losses 121 (3 ) — Finance costs 284 915 200 Finance income (339 ) (55 ) (74 ) Loss/(gain) on unrealized foreign exchange 493 (793 ) 134 Gain on bargain purchase — (49,429 ) — Changes in operating assets and liabilities: Trade receivables 18,975 (17,961 ) (2,727 ) Contract assets 764 (1,505 ) 1,139 Inventories (2,329 ) (20,817 ) (360 ) Prepayment and other assets 809 418 (1,219 ) Trade receivables due from related parties — 284 (428 ) Trade and other payables (32,239 ) 26,157 (2,224 ) Employee benefits obligation 59 11 24 51,653 30,969 (2,112 ) Cash provided by operations: Interest received 339 55 74 Income taxes paid (11,490 ) (6,979 ) (852 ) Net cash provided by/(used in) operating activities 40,502 24,045 (2,890 ) Investing activities Proceeds from sale of property, plant and equipment — 698 — Cash payment for management buyout — (2,000 ) — Acquisition of property, plant and equipment (2,863 ) (3,238 ) (1,200 ) Acquisition of intangible asset — (11 ) — Repayment from/(loan to) related parties — — 20,981 Amount due from a related party 1 (1,585 ) — Net cash (used in)/provided by investing activities (2,862 ) (6,136 ) 19,781 Financing activities Advances from potential investors — 5,000 — Proceeds from loans and borrowings — — 874 Proceeds from loans from related parties — — 8,845 Repayment of loans from related parties — — (28,038 ) Repayment of loans and borrowings (6,504 ) (3,874 ) — Interest paid (253 ) (211 ) (200 ) Payment of lease liabilities (1,302 ) (824 ) (197 ) Net cash (used in)/provided by financing activities (8,059 ) 91 (18,716 ) Effect of foreign exchange on cash, cash equivalents and restricted cash 820 (2,473 ) (75 ) Net increase/(decrease) in cash, cash equivalents and restricted cash 30,401 15,527 (1,900 ) Cash, cash equivalents and restricted cash at beginning of year/period 45,430 29,903 31,803 Cash, cash equivalents and restricted cash at end of year/period 75,831 45,430 29,903 Less: Restricted cash, non-current 1,189 367 1,150 Less: Restricted cash, current 1,692 1,593 1,087 Cash and cash equivalents at end of year/period 72,950 43,470 27,666
